Switching Among Biosimilars: A Review of Clinical Evidence

• Váldodahkkit: Eleonora Allocati (Dahkki), Brian Godman (Dahkki), Marco Gobbi (Dahkki), Silvio Garattini (Dahkki), Rita Banzi (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Biological medicines have improved patients' outcomes, but their high costs may limit access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality, safety, and efficacy to an already licensed originator biological product, could increase competition and decrease...